All posts from Zacks
Zacks in Our Research. Your Success.,

Horizon Pharma Plunges on Bleak Q1 and 1H16 Guidance

Horizon Pharma plc’s HZNP shares tumbled 26.3% after the company revealed net sales and adjusted EBITDA expectations for the first and second quarter of 2016 through an updated investor presentation that was filed with the SEC.

However, the company reiterated its 2016 guidance that was provided during the acquisition of Crealta Holdings early this year (Jan 2016). For 2016, Horizon Pharma continues to expect net sales in the range of $1.025 billion to $1.050 billion, representing year-over-year growth of 37% at the midpoint. The Zacks Consensus Estimate for revenues is currently $1.036 billion. It still expects adjusted EBITDA in the range of $505 million to $520 million, representing year-over-year growth of 41% at the midpoint.

In first-quarter 2016, the company expects to record 19–20% of total net sales for the year, representing year-over-year growth of 79% at the midpoint. However, the guidance is significantly below the Zacks Consensus Estimate of $240 million.

While 22–23% of net sales are expected to come in the second quarter of 2016, the company projects 57–59% of net sales in the second half of 2016.

As far as adjusted EBITDA is concerned, the company anticipates to generate 13–14% (34% of sales) and 21–22% (47% of sales) of adjusted EBITDA in the first and second quarters of 2016, respectively. It expects to pick up pace in the second half of 2016 by reporting adjusted EBITDA of 64–66%.

Horizon Pharma also divulged prescription results for some of its products in the first quarter of 2016. While total prescriptions of Duexis and Vimovo represented substantial year-over-growth of 78% and 38% respectively, Pennsaid 2% increased a whopping 218% year over year. Overall, the Primary Care unit soared 89% year over year while Rayos shot up 117% year over year.

The company expects to remain active on the acquisition front in 2016.

Horizon Pharma is a Zacks Rank #2 (Buy) stock. Some well-ranked stocks in the health care sector include AMAG Pharmaceuticals, Inc. AMAG, Anika Therapeutics Inc. ANIK and Gilead Sciences Inc. GILD. All three stocks sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. blog">Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AMAG PHARMA INC (AMAG): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
HORIZON PHARMA (HZNP): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research